Menu Search
Equities

Abbott Laboratories

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ABL:BRN

Abbott Laboratories

Actions
  • Price (CHF)86.62
  • Today's Change-0.459 / -0.53%
  • Shares traded3.00
  • 1 Year change-26.27%
  • Beta0.7393
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
OPERATIONS
Net income13,4025,7236,933
Depreciation/depletion1,3401,2771,254
Non-Cash items1,155770900
Cash taxes paid, supplemental1,7231,4751,864
Cash interest paid, supplemental604662563
Changes in working capital(9217)(2475)(1519)
Total cash from operations8,5587,2619,581
INVESTING
Capital expenditures(2207)(2202)(1777)
Other investing and cash flow items, total(131)(931)37
Total cash from investing(2338)(3133)(1740)
FINANCING
Financing cash flow items------
Total cash dividends paid(3836)(3556)(3309)
Issuance (retirement) of stock, net(1031)(1060)(3628)
Issuance (retirement) of debt, net(537)(2475)(699)
Total cash from financing(5404)(7091)(7636)
NET CHANGE IN CASH
Foreign exchange effects(96)(23)(122)
Net change in cash720(2986)83
Net cash-begin balance/reserved for future use6,8969,8829,799
Net cash-end balance/reserved for future use7,6166,8969,882
SUPPLEMENTAL INCOME
Depreciation, supplemental1,3401,2771,254
Cash interest paid, supplemental604662563
Cash taxes paid, supplemental1,7231,4751,864
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.